I am a healthcare professional in the UK
I am a patient or member of the public
Introducing LIVTENCITY® <span class="custom-triangle-down-icon"></span> (maribavir) to your MDT
1 minute
Introducing LIVTENCITY▼ (maribavir) to your MDT
Explore a series of informative videos on LIVTENCITY, offering insights into its use for managing CMV infections in transplant recipients.
An introduction to LIVTENCITY (maribavir)
In this video, Dr Sowsan Atabani discusses data from the SOLSTICE study, which was designed to investigate the efficacy and safety of LIVTENCITY compared to investigator assigned therapy in stem cell or solid organ recipients with CMV infection.
Brightcove Video
LIVTENCITY (maribavir) and healthcare resource utilisation
In this video, Dr Adnan Sharif explores the healthcare utilisation costs associated with post-transplant CMV, especially in the context of refractory and resistant CMV.
Brightcove Video
Current treatments in post-transplant CMV infections and case studies
In this video, Janette Chu explores current treatment options in post-transplant CMV infections, along with two patient case studies who were treated with LIVTENCITY.
Brightcove Video
Panel discussion
In this video, our panel discuss interesting statistics obtained from poll questions ran during the webinar, as well as answering your questions on administration, monitoring and refractory CMV thresholds of LIVTENCITY and more.
Brightcove Video
You might be interested in
article
6 minutes
A summary of the safety profile of LIVTENCITY, including adverse event data and tolerability findings from clinical studies.
article
3 minutes
CMV is one of the most common infections experienced by transplant recipients
article
4 minutes
An overview of the pivotal Phase 3 SOLSTICE trial, outlining the study design, patient population, and methodology that underpin the clinical evidence for LIVTENCITY.
